AGARWALEYE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.1
| Stock Code | AGARWALEYE | Market Cap | 15,176 Cr. | Current Price | 479 ₹ | High / Low | 568 ₹ |
| Stock P/E | 352 | Book Value | 62.9 ₹ | Dividend Yield | 0.00 % | ROCE | 5.58 % |
| ROE | 2.19 % | Face Value | 1.00 ₹ | DMA 50 | 449 ₹ | DMA 200 | 454 ₹ |
| Chg in FII Hold | -0.12 % | Chg in DII Hold | 0.05 % | PAT Qtr | 12.6 Cr. | PAT Prev Qtr | 14.6 Cr. |
| RSI | 66.3 | MACD | 5.40 | Volume | 5,04,372 | Avg Vol 1Wk | 1,72,604 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | -38.0 | Debt to equity | 0.34 |
| 52w Index | 63.0 % | Qtr Profit Var | -56.7 % | EPS | 1.25 ₹ | Industry PE | 48.6 |
📊 Financial Overview: Agarwal Eye Hospital (AGARWALEYE) shows weak fundamentals. ROE is 2.19% and ROCE is 5.58%, reflecting poor efficiency. Debt-to-equity is 0.34, indicating moderate leverage. Dividend yield is 0%, with no payouts. Quarterly PAT declined from ₹14.6 Cr. to ₹12.6 Cr., showing a -56.7% variation, highlighting earnings volatility.
💹 Valuation Indicators: Current P/E of 352 is extremely high compared to the industry average of 48.6, suggesting severe overvaluation. P/B ratio is ~7.6 (479/62.9), which is expensive. PEG ratio is negative (-38.0), signaling unsustainable growth prospects. Intrinsic value appears much lower than current price, making fresh entry unattractive.
🏢 Business Model & Advantage: Agarwal Eye Hospital operates in healthcare services, specializing in ophthalmology and eye care. Its competitive advantage lies in brand recognition, specialized expertise, and growing demand for healthcare services. However, profitability pressures, high debt, and stretched valuations limit financial attractiveness.
📈 Entry Zone: A favorable entry zone lies between ₹420–450, closer to intrinsic value and support levels. Current price (₹479) is above this zone, making staggered accumulation advisable only for long-term investors.
🔒 Long-Term Holding Guidance: Agarwal Eye Hospital is a recognized healthcare provider, but extremely high valuations, weak return ratios, and volatile earnings make it risky. Long-term investors should hold cautiously, monitoring profitability and debt management.
Positive
- 🌟 Recognized brand in ophthalmology and healthcare services
- 🌟 Institutional interest increased slightly (DII +0.05%)
- 🌟 Growing demand for specialized healthcare services
Limitation
- ⚠️ Extremely high P/E (352) vs industry average (48.6)
- ⚠️ Very low ROE (2.19%) and ROCE (5.58%)
- ⚠️ PEG ratio negative (-38.0)
- ⚠️ Dividend yield 0%
Company Negative News
- 📉 PAT declined from ₹14.6 Cr. to ₹12.6 Cr.
- 📉 FII holdings reduced (-0.12%)
Company Positive News
- 📈 DII holdings increased slightly (+0.05%)
- 📈 Strong brand recognition in healthcare services
Industry
- 🏦 Industry P/E at 48.6 reflects premium valuations
- 🏦 Healthcare sector supported by rising demand for specialized services
Conclusion
✅ Agarwal Eye Hospital has brand recognition and industry relevance, but extremely high valuations, weak return ratios, and volatile earnings make it unattractive at current levels. A better entry zone lies between ₹420–450. Long-term investors should hold cautiously, awaiting profitability recovery and debt reduction.
Would you like me to also prepare a healthcare sector outlook to evaluate how rising demand and policy support could influence Agarwal Eye Hospital’s long-term trajectory?